EWMA 2013 - Ep561 - EXPERIENCE OF THE TLC-NOSF DRESSING* IN THE MANAGEMENT OF DIABETIC FOOT ULCERS

468 views

Published on

Dr V. SRIMUNINNIMIT(1), Dr T. VEERAPREEYAKOL(2)
L. THOMASSIN(3)

(1) Division of Plastic surgery, Ramathibodi Hospital Faculty of Medecine, Mahidol University, Bangkok, Thailand
(2) Division of General surgery, Khon Kaen Hospital, Khon Kaen, Thailand
(3) Laboratoires Urgo, Chenôve, France.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

EWMA 2013 - Ep561 - EXPERIENCE OF THE TLC-NOSF DRESSING* IN THE MANAGEMENT OF DIABETIC FOOT ULCERS

  1. 1. EXPERIENCE OF THE TLC-NOSF DRESSING* IN THE MANAGEMENT OF DIABETIC FOOT ULCERS Dr V. SRIMUNINNIMIT(1), Dr T. VEERAPREEYAKOL(2) L. THOMASSIN(3) (1) Division of Plastic surgery, Ramathibodi Hospital Faculty of Medecine, Mahidol University, Bangkok, Thailand (2) Division of General surgery, Khon Kaen Hospital, Khon Kaen, Thailand (3) Laboratoires Urgo, Chenôve, France. *Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart® Contact
  2. 2. INTRODUCTION Diabetic foot ulcers are prone to delayed healing (stagnation/aggravation) due to abnormally high local proteolytic activity (excess liberation of matrix metalloproteinases, or MMPs). The NOSF (Nano-Oligo Saccharide Factor) is an innovative compound which has demonstrated MMP-inhibiting properties. The authors report the initial results of their clinical tests using a lipido-colloid dressing impregnated with NOSF* in the local treatment of foot ulcers in diabetic patients, associated with off-loading of the affected foot. In these clinical cases, the new compound (NOSF) offers the possibility to equilibrate the wound micro environment and relaunch the healing process until healing is complete (case 1) or almost complete (case 2). *Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart® Contact
  3. 3. Figure 3 76 years-old-female patient, with Type 2 Diabetes Mellitus and ABPI<0,6. The wound had been stagnant for more than 4 months, and the tendon visible at the wound bed. It was previously treated with AG dressings, Zinc Hyaluronate and PDGF gel. Upon admission, the wound surface area measured 0,5 x 1 cm² with a depth of 1,0 x 0,7 x 0,4 x 0,5 cm² (fig.1). After an angioplasty and 8 weeks treatment with TLC-NOSF dressing*, the wound surface area is 0,3 x 0,2 cm². The cavity size was significantly reduced in both circumference and depth with 90% reepithelialisation (fig.2). After 12 weeks treatment, complete healing was observed (fig.3). Figure 2 Figure 1 CLINICAL CASE STUDY 1 *Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart® Contact
  4. 4. 56 years-old female patient, with Type 2 Diabetes Mellitus and lower member arteritis. The 5th toe was amputated and healing delayed for approximately 3 months. At inclusion, the wound surface area was 3 x 3,5 cm² (fig.4). After 1 week of treatment with TLC-NOSF dressing*, the wound presented with signs of localized infection, and the decision was made to switch to a silver dressing for a period of 2 weeks. Once the infection had gone, treatment was continued with the TLC-NOSF dressing* and after 5 weeks the wound surface area had significantly decreased, with a measurement of 0,8 x 0,4 cm² (fig.5). Figure 4 Figure 5 CLINICAL CASE STUDY 2 *Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart® Contact
  5. 5. These clinical cases illustrate the efficacy, and high level of tolerance and conformability of the TLC-NOSF dressings* in the local treatment of diabetic foot ulcers associated with off-loading of the affected foot. CONCLUSION *Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart® Contact

×